Trace Neuroscience
Trace Neuroscience is a biopharmaceutical company developing novel genomic therapies to restore UNC13A protein function in neurodegenerative diseases. Their lead program focuses on an antisense oligonucleotide for amyotrophic lateral sclerosis (ALS) to improve muscle function. The company aims to expand the promise of genomic medicine for individuals with neurodegenerative diseases.
Funding Round: Series A
Funding Amount: $101M
Date: 12-Nov-2024
Investors: Third Rock Ventures, Atlas Venture, GV, RA Capital Management
Markets: Biopharmaceutical, Genomic Medicine, Neurodegenerative Diseases, Biotechnology, Health Care, Life Science
HQ: South San Francisco, California, United States
Founded: 2024
Website: https://www.traceneuro.com
LinkedIn: https://www.linkedin.com/company/traceneuroscience
Twitter: https://x.com/TraceNeuro
Crunchbase: https://www.crunchbase.com/organization/trace-neuroscience
Leave a Comment
Comments
No comments yet.